CL2017000379A1 - Compuestos de pirrolopirimidina usados como agonistas del receptor de tipo toll. 7 (tlr7) - Google Patents

Compuestos de pirrolopirimidina usados como agonistas del receptor de tipo toll. 7 (tlr7)

Info

Publication number
CL2017000379A1
CL2017000379A1 CL2017000379A CL2017000379A CL2017000379A1 CL 2017000379 A1 CL2017000379 A1 CL 2017000379A1 CL 2017000379 A CL2017000379 A CL 2017000379A CL 2017000379 A CL2017000379 A CL 2017000379A CL 2017000379 A1 CL2017000379 A1 CL 2017000379A1
Authority
CL
Chile
Prior art keywords
tlr7
compounds used
receptor agonists
toll receptor
pyrrolopyrimidine compounds
Prior art date
Application number
CL2017000379A
Other languages
English (en)
Inventor
Zhaozhong Ding
Hao Wu
Fei Sun
Lifang Wu
Ling Yang
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN201410405136.0A external-priority patent/CN105367576A/zh
Application filed by Chia Tai Tianqing Pharmaceutical Group Co Ltd filed Critical Chia Tai Tianqing Pharmaceutical Group Co Ltd
Publication of CL2017000379A1 publication Critical patent/CL2017000379A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)

Abstract

<p>La presente invención se refiere a un compuesto de pirrolopirimidina como agonista de TLR7, y particularmente se refiere a un compuesto de la fórmula (l) o una sal farmacéuticamente aceptable del mismo, un procedimiento de fabricación del mismo, una composición farmacéutica que contiene dicho compuesto, y su uso en la fabricación de un medicamento contra una infección viral.</p>
CL2017000379A 2014-08-15 2017-02-14 Compuestos de pirrolopirimidina usados como agonistas del receptor de tipo toll. 7 (tlr7) CL2017000379A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201410405136.0A CN105367576A (zh) 2014-08-15 2014-08-15 作为tlr7激动剂的吡咯并嘧啶化合物
CN201510392499 2015-07-06

Publications (1)

Publication Number Publication Date
CL2017000379A1 true CL2017000379A1 (es) 2018-04-27

Family

ID=55303885

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017000379A CL2017000379A1 (es) 2014-08-15 2017-02-14 Compuestos de pirrolopirimidina usados como agonistas del receptor de tipo toll. 7 (tlr7)

Country Status (26)

Country Link
US (2) US9962388B2 (es)
EP (1) EP3190113B1 (es)
JP (2) JP6328341B2 (es)
KR (2) KR102215609B1 (es)
CN (4) CN112898308B (es)
AU (3) AU2015303558B2 (es)
BR (1) BR112017002811B1 (es)
CA (1) CA2958097C (es)
CL (1) CL2017000379A1 (es)
DK (1) DK3190113T3 (es)
EA (1) EA032824B1 (es)
ES (1) ES2875313T3 (es)
HR (1) HRP20210927T1 (es)
HU (1) HUE054672T2 (es)
IL (2) IL250586B (es)
LT (1) LT3190113T (es)
MX (1) MX386981B (es)
MY (1) MY190026A (es)
PH (2) PH12017500281B1 (es)
PL (1) PL3190113T3 (es)
PT (1) PT3190113T (es)
SG (2) SG10201809918RA (es)
SI (1) SI3190113T1 (es)
UA (1) UA117634C2 (es)
WO (1) WO2016023511A1 (es)
ZA (1) ZA201803736B (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10442811B2 (en) 2016-02-05 2019-10-15 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Crystal form A of 2-butoxy-7-(4-(pyrrolidin-1-ylmethyl)benzyl)-5H-pyrrolo[3,2-D] pyrimidin-4-amine, preparation process and use thereof

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10973920B2 (en) 2014-06-30 2021-04-13 Glykos Finland Oy Saccharide derivative of a toxic payload and antibody conjugates thereof
CN112898308B (zh) * 2014-08-15 2026-08-07 正大天晴药业集团股份有限公司 作为tlr7激动剂的吡咯并嘧啶化合物
NZ775222A (en) 2015-05-08 2024-09-27 Hoffmann La Roche Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection
CR20180229A (es) 2015-10-29 2018-08-24 Novartis Ag Conjugados de anticuerpos que comprenden un agonista del receptor tipo toll
KR102112192B1 (ko) * 2015-11-05 2020-05-19 치아타이 티안큉 파마수티컬 그룹 주식회사 Tlr7 효능제로서의 7-(티아졸-5-일)피롤로피리미딘 화합물
CN107043377A (zh) * 2016-02-05 2017-08-15 正大天晴药业集团股份有限公司 一种tlr7激动剂的三氟乙酸盐、晶型b及其制备方法、药物组合物和用途
CN107043378A (zh) * 2016-02-05 2017-08-15 正大天晴药业集团股份有限公司 一种吡咯并[3,2-d]嘧啶类化合物的制备方法及其中间体
CN107043380A (zh) * 2016-02-05 2017-08-15 正大天晴药业集团股份有限公司 一种tlr7激动剂的马来酸盐、其晶型c、晶型d、晶型e、制备方法和用途
SI3464336T1 (sl) 2016-06-01 2022-06-30 Athira Pharma, Inc. Spojine
JOP20190024A1 (ar) 2016-08-26 2019-02-19 Gilead Sciences Inc مركبات بيروليزين بها استبدال واستخداماتها
RU2751349C2 (ru) 2016-08-29 2021-07-13 Ф. Хоффманн-Ля Рош Аг 7-замещенные сульфонимидоилпуриноны для лечения и профилактики вирусной инфекции
EP4059934B1 (en) 2016-09-09 2026-07-29 Novartis AG Compounds and compositions as inhibitors of endosomal toll-like receptors
CA3034185A1 (en) 2016-09-13 2018-03-22 F. Hoffmann-La Roche Ag Combined treatment with a tlr7 agonist and an hbv capsid assembly inhibitor
KR20230010826A (ko) 2016-10-14 2023-01-19 프리시젼 바이오사이언시스 인코포레이티드 B형 간염 바이러스 게놈 내의 인식 서열에 대해 특이적인 조작된 메가뉴클레아제
WO2018078149A1 (en) * 2016-10-31 2018-05-03 F. Hoffmann-La Roche Ag Novel cyclicsulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection
EP3539963A4 (en) 2016-11-11 2020-05-13 Hepo Pharmaceutical Co., Ltd. NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, PREPARATION METHOD, INTERMEDIATE, PHARMACEUTICAL COMPOSITION AND USE
KR20190084991A (ko) * 2016-11-28 2019-07-17 지앙수 헨그루이 메디슨 컴퍼니 리미티드 피라졸로-헤테로아릴 유도체, 이의 제조 방법 및 의학적 용도
JP2020520379A (ja) 2017-05-18 2020-07-09 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司Ｊｉａｎｇｓｕ Ｈｅｎｇｒｕｉ Ｍｅｄｉｃｉｎｅ Ｃｏ．， Ｌｔｄ． ヘテロアリール−ピラゾール誘導体ならびにその調製方法および医学的適用
US10508115B2 (en) 2017-08-16 2019-12-17 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor
US10472361B2 (en) 2017-08-16 2019-11-12 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a benzotriazole moiety, conjugates thereof, and methods and uses therefor
US10457681B2 (en) 2017-08-16 2019-10-29 Bristol_Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a tricyclic moiety, conjugates thereof, and methods and uses therefor
US10487084B2 (en) 2017-08-16 2019-11-26 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a heterobiaryl moiety, conjugates thereof, and methods and uses therefor
US10494370B2 (en) 2017-08-16 2019-12-03 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a pyridine or pyrazine moiety, conjugates thereof, and methods and uses therefor
CN111448190B (zh) 2017-11-14 2023-09-26 百时美施贵宝公司 取代的吲哚化合物
US12030878B2 (en) 2017-12-15 2024-07-09 Bristol-Myers Squibb Company Substituted indole ether compounds
MX2020006168A (es) * 2017-12-18 2020-08-13 Bristol Myers Squibb Co Compuestos de 4-azaindol.
WO2019126081A1 (en) 2017-12-19 2019-06-27 Bristol-Myers Squibb Company Amide substituted indole compounds useful as tlr inhibitors
EP3728253B1 (en) * 2017-12-19 2024-03-27 Bristol-Myers Squibb Company 6-azaindole compounds
EA202091474A1 (ru) 2017-12-19 2020-11-18 Бристол-Маерс Сквибб Компани Замещенные индольные соединения, применимые в качестве ингибиторов tlr
JP7037667B2 (ja) 2017-12-20 2022-03-16 インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール，ヴイ．ヴイ．アイ． Ｓｔｉｎｇアダプタータンパク質を活性化するホスホン酸結合を有する３’３’環状ジヌクレオチド
US11203610B2 (en) 2017-12-20 2021-12-21 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
KR102730859B1 (ko) 2017-12-20 2024-11-15 브리스톨-마이어스 스큅 컴퍼니 아릴 및 헤테로아릴 치환된 인돌 화합물
JP7287967B2 (ja) 2017-12-20 2023-06-06 ブリストル－マイヤーズ スクイブ カンパニー Ｔｌｒ阻害剤として有効なアミノインドール化合物
EA202091530A1 (ru) * 2017-12-20 2020-09-14 Бристол-Маерс Сквибб Компани Диазаиндольные соединения
WO2019155042A1 (en) 2018-02-12 2019-08-15 F. Hoffmann-La Roche Ag Novel sulfone compounds and derivatives for the treatment and prophylaxis of virus infection
JP7050165B2 (ja) 2018-02-26 2022-04-07 ギリアード サイエンシーズ， インコーポレイテッド Ｈｂｖ複製阻害剤としての置換ピロリジン化合物
WO2019195181A1 (en) 2018-04-05 2019-10-10 Gilead Sciences, Inc. Antibodies and fragments thereof that bind hepatitis b virus protein x
TW202005654A (zh) 2018-04-06 2020-02-01 捷克科學院有機化學與生物化學研究所 ２，２，─環二核苷酸
TWI833744B (zh) 2018-04-06 2024-03-01 捷克科學院有機化學與生物化學研究所 3'3'-環二核苷酸
TWI818007B (zh) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-環二核苷酸
US11142750B2 (en) 2018-04-12 2021-10-12 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
WO2019209811A1 (en) 2018-04-24 2019-10-31 Bristol-Myers Squibb Company Macrocyclic toll-like receptor 7 (tlr7) agonists
WO2019211799A1 (en) 2018-05-03 2019-11-07 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide
CN112105620B (zh) * 2018-05-25 2026-02-24 正大天晴药业集团股份有限公司 用于治疗肺癌的tlr7激动剂及其药物组合
WO2020028097A1 (en) 2018-08-01 2020-02-06 Gilead Sciences, Inc. Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
US11554120B2 (en) 2018-08-03 2023-01-17 Bristol-Myers Squibb Company 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor
AU2019357451A1 (en) * 2018-10-12 2021-06-03 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. TLR7 agonist for treating colorectal cancer and pharmaceutical combination thereof
ES2963696T3 (es) 2018-10-24 2024-04-01 Bristol Myers Squibb Co Compuestos diméricos de indol sustituidos
US12172995B2 (en) 2018-10-24 2024-12-24 Bristol-Myers Squibb Company Substituted indole and indazole compounds
EP3873608A1 (en) 2018-10-31 2021-09-08 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
EP4371987B9 (en) 2018-10-31 2025-11-26 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds as hpk1 inhibitors
KR102853071B1 (ko) * 2019-02-07 2025-09-02 베이진 엘티디 Tlr7 작용제로서의 이미다조[2,1-f][1,2,4]트리아진-4-아민 유도체
BR112021015577A2 (pt) 2019-02-08 2021-10-05 Research & Business Foundation Sungkyunkwan University Complexo-colesterol agonista do receptor toll-like 7 ou 8 e uso do mesmo
WO2020178768A1 (en) 2019-03-07 2020-09-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
CN113574063B (zh) 2019-03-07 2025-03-18 捷克共和国有机化学与生物化学研究所 3’3’-环二核苷酸及其前药
WO2020178769A1 (en) 2019-03-07 2020-09-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotides and prodrugs thereof
ES3070986T3 (en) * 2019-03-15 2026-06-18 Chia Tai Tianqing Pharmaceutical Group Co Ltd Toll-like receptor agonists for use in the treatment of hepatitis b
TWI751517B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TW202210480A (zh) 2019-04-17 2022-03-16 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
SG11202111488YA (en) * 2019-04-23 2021-11-29 Chia Tai Tianqing Pharmaceutical Group Co Ltd Solid pharmaceutical composition comprising tlr7 agonist
KR102904576B1 (ko) 2019-05-09 2025-12-24 브리스톨-마이어스 스큅 컴퍼니 치환된 벤즈이미다졸론 화합물
US11453681B2 (en) 2019-05-23 2022-09-27 Gilead Sciences, Inc. Substituted eneoxindoles and uses thereof
JP7595643B2 (ja) * 2019-08-02 2024-12-06 ベイジーン リミテッド Ｔｌｒ８アゴニストとしてのイミダゾ［２，１－ｆ］［１，２，４］トリアジン－４－アミン誘導体
US20220296619A1 (en) 2019-08-19 2022-09-22 Gilead Sciences, Inc. Pharmaceutical formulations of tenofovir alafenamide
EP4029503B1 (en) * 2019-09-29 2026-01-28 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Drug combinations of entecavir and a tlr7 agonist for use in the treatment of hbv
HRP20241379T1 (hr) 2019-09-30 2024-12-20 Gilead Sciences, Inc. Cjepiva za hbv i postupci za liječenje hbv
WO2021067326A1 (en) 2019-10-01 2021-04-08 Bristol-Myers Squibb Company Substituted bicyclic heteroaryl compounds
CN114829350B (zh) 2019-10-04 2024-05-28 百时美施贵宝公司 经取代的咔唑化合物
US12410418B2 (en) 2019-12-06 2025-09-09 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
JP7684316B2 (ja) 2020-01-27 2025-05-27 ブリストル－マイヤーズ スクイブ カンパニー トール様受容体７（ＴＬＲ７）アゴニストとしての１Ｈ－ピラゾロ［４，３－ｄ］ピリミジン化合物
CN115151547A (zh) 2020-01-27 2022-10-04 百时美施贵宝公司 作为Toll样受体7(TLR7)激动剂的1H-吡唑并[4,3-d]嘧啶化合物
JP7712941B2 (ja) 2020-01-27 2025-07-24 ブリストル－マイヤーズ スクイブ カンパニー トール様受容体７（ＴＬＲ７）アゴニストとしての１Ｈ－ピラゾロ［４，３－ｄ］ピリミジン化合物
KR20220132594A (ko) 2020-01-27 2022-09-30 브리스톨-마이어스 스큅 컴퍼니 톨-유사 수용체 7 (TLR7) 효능제로서의 1H-피라졸로[4,3-d]피리미딘 화합물
CN115210235A (zh) 2020-01-27 2022-10-18 百时美施贵宝公司 作为Toll样受体7(TLR7)激动剂的1H-吡唑并[4,3-d]嘧啶化合物
JP2023512206A (ja) 2020-01-27 2023-03-24 ブリストル－マイヤーズ スクイブ カンパニー トール様受容体７（ＴＬＲ７）アゴニストとしての１Ｈ－ピラゾロ［４，３－ｄ］ピリミジン化合物
CN115279765B (zh) 2020-01-27 2024-11-12 百时美施贵宝公司 作为Toll样受体7(TLR7)激动剂的1H-吡唑并[4,3-d]嘧啶化合物
US20230127326A1 (en) 2020-01-27 2023-04-27 Bristol-Myers Squibb Company C3-SUBSTITUTED 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
WO2021154662A1 (en) 2020-01-27 2021-08-05 Bristol-Myers Squibb Company 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
CN115666637A (zh) 2020-03-02 2023-01-31 蛋白科技先锋 基于病原体细胞壁骨架的模拟活病原体的纳米粒子及其制备方法
KR102987126B1 (ko) 2020-03-20 2026-07-07 길리애드 사이언시즈, 인코포레이티드 4'-c-치환된-2-할로-2'-데옥시아데노신 뉴클레오시드의 프로드러그 및 이의 제조 및 사용 방법
CN116057045B (zh) 2020-06-05 2026-06-09 金耐特生物制药公司 成纤维细胞生长因子受体激酶抑制剂
WO2022031021A1 (ko) 2020-08-04 2022-02-10 성균관대학교산학협력단 동력학적 제어가 가능한 아주번트를 포함하는 mrna 백신
US20230277525A1 (en) 2020-08-04 2023-09-07 Progeneer Inc Conjugate of functional drug and toll-like receptor 7 or 8 agonist of which active site is temporarily inactivated and use thereof
EP4194008A4 (en) 2020-08-04 2025-01-08 Progeneer Inc. Kinetically acting adjuvant ensemble
WO2022156678A1 (zh) * 2021-01-20 2022-07-28 上海维申医药有限公司 大环tlr7激动剂、其制备方法、药物组合物及其用途
WO2022206752A1 (zh) * 2021-03-29 2022-10-06 正大天晴药业集团股份有限公司 Toll样受体7激动剂和抗PD-L1抗体的药物联合
US20240269142A1 (en) 2021-05-13 2024-08-15 Gilead Sciences, Inc. COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS
MX2023014762A (es) 2021-06-23 2024-01-15 Gilead Sciences Inc Compuestos moduladores de diacilglicerol quinasa.
EP4359413A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
JP7651018B2 (ja) 2021-06-23 2025-03-25 ギリアード サイエンシーズ， インコーポレイテッド ジアシルグリセロールキナーゼ調節化合物
CN117355531A (zh) 2021-06-23 2024-01-05 吉利德科学公司 二酰基甘油激酶调节化合物
CN114409654A (zh) * 2021-12-30 2022-04-29 安徽普利药业有限公司 一种btk抑制剂的中间体合成方法
WO2025110816A1 (ko) 2023-11-23 2025-05-30 프로지니어 주식회사 암의 치료를 위한 활성화 부위가 일시적으로 비활성화된 톨-유사 수용체 7 또는 8 작용자와 항암 치료의 병용요법
WO2025240246A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with ribavirin
TW202608468A (zh) 2024-05-13 2026-03-01 美商基利科學股份有限公司 組合療法
US20250345390A1 (en) 2024-05-13 2025-11-13 Gilead Sciences, Inc. Combination therapies
WO2025240242A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with ribavirin

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9020931D0 (en) * 1990-09-26 1990-11-07 Wellcome Found Heterocyclic compounds
JP4667543B2 (ja) 1996-07-03 2011-04-13 大日本住友製薬株式会社 新規プリン誘導体
JP4375901B2 (ja) 1997-11-28 2009-12-02 大日本住友製薬株式会社 新規な複素環化合物
CN1845745B (zh) * 2003-09-05 2011-11-02 安那迪斯药品股份有限公司 Tlr7配体及其前药在制备用于治疗丙型肝炎病毒感染的药物中的用途
CA2620182A1 (en) * 2005-08-22 2007-03-01 Dennis A. Carson Tlr agonists
EP2510946B1 (en) * 2007-02-07 2015-08-05 The Regents of The University of California Conjugates of synthetic tlr agonists and uses therefor
TW200902018A (en) * 2007-03-20 2009-01-16 Dainippon Sumitomo Pharma Co Novel adenine compound
EP2170888B1 (en) * 2007-06-29 2015-04-22 Gilead Sciences, Inc. Purine derivatives and their use as modulators of toll-like receptor 7
ATE501136T1 (de) 2007-08-03 2011-03-15 Pfizer Ltd Imidazopyridinone
UY32306A (es) 2008-12-09 2010-07-30 Gilead Sciences Inc Derivados de pteridinona y pirimidinodiazepinona y composiciones farmacéuticas que modulan en forma selectiva los receptores tipo toll, métodos y usos
NZ603310A (en) * 2010-05-21 2015-01-30 Gilead Sciences Inc Heterocyclic flaviviridae virus inhibitors
DE102011008352A1 (de) * 2011-01-12 2012-07-12 Merck Patent Gmbh 5-([1,2,3]Triazol-4-yl)-7H-pyrrolo-[2,3-d]pyrimidinderivate
JP5813785B2 (ja) * 2011-02-04 2015-11-17 デュケイン ユニバーシティー オブ ザ ホリー スピリット 抗チューブリン活性を有する二環式および三環式のピリミジンチロシンキナーゼ阻害剤ならびに患者の処置方法
EP2674170B1 (en) * 2012-06-15 2014-11-19 Invivogen Novel compositions of TLR7 and/or TLR8 agonists conjugated to lipids
MX386924B (es) * 2012-10-10 2025-03-19 Janssen Sciences Ireland Uc Derivados pirrolo[3,2-d]pirimidínicos para el tratamiento de infecciones víricas y otras enfermedades.
JP6216387B2 (ja) * 2012-11-20 2017-10-18 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ 新規化合物
KR20150085081A (ko) * 2012-11-20 2015-07-22 글락소스미스클라인 엘엘씨 신규 화합물
SMT201700378T1 (it) * 2012-11-20 2017-09-07 Glaxosmithkline Llc Nuovi composti
KR20160124157A (ko) 2014-02-20 2016-10-26 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 인간 인터페론의 유도인자로서의 피롤로[3,2]피리미딘 유도체
SG11201608299TA (en) 2014-05-01 2016-11-29 Novartis Ag Compounds and compositions as toll-like receptor 7 agonists
WO2015168269A1 (en) 2014-05-01 2015-11-05 Novartis Ag Compounds and compositions as toll-like receptor 7 agonists
CN112898308B (zh) * 2014-08-15 2026-08-07 正大天晴药业集团股份有限公司 作为tlr7激动剂的吡咯并嘧啶化合物
CN105732635A (zh) 2014-12-29 2016-07-06 南京明德新药研发股份有限公司 一类Toll样受体7激动剂

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10442811B2 (en) 2016-02-05 2019-10-15 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Crystal form A of 2-butoxy-7-(4-(pyrrolidin-1-ylmethyl)benzyl)-5H-pyrrolo[3,2-D] pyrimidin-4-amine, preparation process and use thereof
US10947245B2 (en) 2016-02-05 2021-03-16 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Crystal form A of 2-butoxy-7-(4-(pyrrolidin-1-ylmethyl)benzyl)-5H-pyrrolo[3,2-d]pyrimidin-4-amine for inhibiting toll-like receptor activity

Also Published As

Publication number Publication date
SI3190113T1 (sl) 2021-09-30
CN106661034A (zh) 2017-05-10
CA2958097C (en) 2019-05-14
PH12020551089A1 (en) 2021-05-10
IL250586A0 (en) 2017-04-30
KR20190098277A (ko) 2019-08-21
CN106661034B (zh) 2019-11-29
US10555949B2 (en) 2020-02-11
BR112017002811A2 (pt) 2017-12-19
EP3190113A4 (en) 2018-01-24
CN110759916B (zh) 2021-02-19
UA117634C2 (uk) 2018-08-27
AU2019253788A1 (en) 2019-11-14
PL3190113T3 (pl) 2021-10-25
LT3190113T (lt) 2021-08-25
SG11201701169XA (en) 2017-03-30
PT3190113T (pt) 2021-06-17
PH12017500281A1 (en) 2017-07-03
MX386981B (es) 2025-03-19
CN110938076B (zh) 2021-08-10
AU2018236899B2 (en) 2019-07-25
NZ730011A (en) 2023-08-25
MY190026A (en) 2022-03-22
EP3190113A1 (en) 2017-07-12
MX2017002028A (es) 2017-08-14
ZA201803736B (en) 2020-08-26
CN110938076A (zh) 2020-03-31
JP2018123160A (ja) 2018-08-09
CN112898308B (zh) 2026-08-07
PH12017500281B1 (en) 2021-01-15
KR102215609B1 (ko) 2021-02-15
HUE054672T2 (hu) 2021-09-28
BR112017002811B1 (pt) 2022-09-06
AU2018236899A1 (en) 2018-10-18
DK3190113T3 (da) 2021-06-07
US20170273983A1 (en) 2017-09-28
KR20170041913A (ko) 2017-04-17
AU2015303558B2 (en) 2018-07-12
AU2019253788B2 (en) 2020-05-28
US20180303832A1 (en) 2018-10-25
AU2019253788C1 (en) 2020-09-17
CN112898308A (zh) 2021-06-04
JP2017524037A (ja) 2017-08-24
ES2875313T3 (es) 2021-11-10
SG10201809918RA (en) 2018-12-28
JP6328341B2 (ja) 2018-05-23
HRP20210927T1 (hr) 2021-09-03
CN110759916A (zh) 2020-02-07
IL276908A (en) 2020-10-29
CA2958097A1 (en) 2016-02-18
IL250586B (en) 2020-09-30
EP3190113B1 (en) 2021-05-19
NZ761639A (en) 2023-08-25
WO2016023511A1 (zh) 2016-02-18
US9962388B2 (en) 2018-05-08
AU2015303558A1 (en) 2017-03-30
EA201790389A1 (ru) 2017-06-30
EA032824B1 (ru) 2019-07-31
JP6639551B2 (ja) 2020-02-05

Similar Documents

Publication Publication Date Title
MX386981B (es) Compuestos de pirrolopirimidina usados como agonistas del receptor de tipo toll 7 (tlr7).
MX2018005708A (es) Compuesto de 7-(tiazol-5-il)pirrolopirimidina como agonista de tlr7.
DOP2019000201A (es) Compuestos inhibidores del vih
CL2017001426A1 (es) Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales.
CL2018000318A1 (es) Compuestos derivados de piridinona, inhibidores de bromodominio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades del cáncer. (solicitud divisional 201600925)
CU20150096A7 (es) Compuestos de amida y composición farmacéutica para el tratamiento de vih
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
CR20130560A (es) Compuestos de bezotiazol y su uso farmacéutico
BR112017010354B8 (pt) Compostos de triazolopirimidina, seu uso, e composição farmacêutica
AR128459A2 (es) Composición farmacéutica sólida comprimida por rodillo y el proceso para su fabricación
EA201691988A1 (ru) Производные бороновой кислоты и их терапевтическое применение
MX377916B (es) Compuestos 4-amino-imidazoquinolina.
MX2016006336A (es) Compuestos pirazolopirimidina.
EA201500383A1 (ru) Производные 1,2,4-триазина для лечения вирусных инфекций
MX2018000280A (es) Oxiesteroles y metodos de uso de los mismos.
CL2017001483A1 (es) Formulación de relación fija de insulina glargina/lixisenatida
BR112017000246A2 (pt) composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto ou de um sal
ECSP16084317A (es) Formulaciones farmacéuticas, procesos para la preparación y métodos de uso
CR20160016A (es) Pirazolpiridinas sustituidas
NI201800071A (es) Compuestos de isoindol
PH12018500378A1 (en) Novel annelated phenoxyacetamides
MX2020003732A (es) Derivado de anillo fusionado como inhibidor del receptor a2a.
DOP2019000021A (es) Derivado de triazolopirazinona útil como un inhibidor de pde1 humana
UY33806A (es) ?compuestos novedosos de imidazoquinolina, composiciones que los contienen y su uso en el tratamiento de enfermedades mediadas por tlr7?
IN2013MU02442A (es)